Morgan Stanley
CTXR icon

Morgan Stanley’s Citius Pharmaceuticals CTXR Stock Holding History

Morgan Stanley’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.23K Sell
1,364
-668
-33% -$540 ﹤0.01% 7400
2025
Q4 		$1.58K Buy
2,032
+1,625
+399% +$2.03K ﹤0.01% 7288
2025
Q3 		$504 Buy
407
+347
+578% +$484 ﹤0.01% 7492
2025
Q2 		$95 Hold
60
– – ﹤0.01% 7657
2025
Q1 		$89 Sell
60
-258
-81% -$618 ﹤0.01% 7592
2024
Q4 		$1.27K Buy
318
+258
+430% +$1.74K ﹤0.01% 7244
2024
Q3 		$751 Sell
60
-330
-85% -$5.55K ﹤0.01% 7263
2024
Q2 		$5.69K Sell
390
-7,277
-95% -$130K ﹤0.01% 6819
2024
Q1 		$172K Sell
7,667
-11,850
-61% -$216K ﹤0.01% 5778
2023
Q4 		$369K Buy
19,517
+16,476
+542% +$312K ﹤0.01% 5734
2023
Q3 		$52K Sell
3,041
-1,120
-27% -$26.6K ﹤0.01% 6152
2023
Q2 		$125K Sell
4,161
-1,299
-24% -$42.8K ﹤0.01% 5847
2023
Q1 		$160K Buy
5,460
+1,005
+23% +$29K ﹤0.01% 5809
2022
Q4 		$88K Sell
4,455
-1,485
-25% -$40.5K ﹤0.01% 6037
2022
Q3 		$179K Sell
5,940
-2,370
-29% -$65.1K ﹤0.01% 5777
2022
Q2 		$191K Buy
8,310
+6,462
+350% +$177K ﹤0.01% 5923
2022
Q1 		$83K Buy
1,848
+229
+14% +$9.04K ﹤0.01% 6433
2021
Q4 		$61K Buy
1,619
+1,123
+226% +$50.9K ﹤0.01% 6715
2021
Q3 		$25K Buy
496
+146
+42% +$7.33K ﹤0.01% 7007
2021
Q2 		$30K Sell
350
-1,250
-78% -$75.1K ﹤0.01% 6855
2021
Q1 		$71K Buy
+1,600
New +$63.7K ﹤0.01% 6184
2019
Q2 		– Sell
-840
Closed -$29K – 6659
2019
Q1 		$29K Buy
+840
New +$24.7K ﹤0.01% 5887
2018
Q4 		– Sell
-2
Closed – – 6611
2018
Q3 		$0 Buy
2
+1
+100% +$48 ﹤0.01% 6723
2018
Q2 		$0 Buy
+1
New +$66 ﹤0.01% 6676
2017
Q4 		– Sell
-8
Closed -$1K – 6578
2017
Q3 		$1K Buy
+8
New +$624 ﹤0.01% 6436

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Morgan Stanley's CTXR Position: Q1 2026 in Review

Morgan Stanley reduced its Citius Pharmaceuticals (CTXR) stake by 33% in Q1 2026, selling an estimated $540 and leaving 1,364 shares worth $1.23K. The position accounts for ﹤0.01% of the portfolio, ranked #7400.

Morgan Stanley first reported a position in CTXR in Q3 2017 and has held it in 25 quarters since. The position peaked at $369K in Q4 2023. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • Morgan Stanley held 1,364 shares of Citius Pharmaceuticals worth $1.23K as of Q1 2026.
  • Morgan Stanley sold 668 Citius Pharmaceuticals shares in Q1 2026, an estimated $540.
  • Citius Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7400 holding.
  • Morgan Stanley first reported a position in Citius Pharmaceuticals in Q3 2017 and has held it in 25 quarters since.
  • Morgan Stanley's Citius Pharmaceuticals position peaked at $369K in Q4 2023.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.